Key Summary
- Five non-executive directors reappointed to the MHRA board
- Terms vary, with most starting in September 2025
- Appointments are merit-based with no political ties declared
The Medicine and Healthcare products Regulatory Agency (MHRA) board has recently reappointed five non-executive directors (NED).
The appointments are implemented with strict adherence to the Cabinet Office Code of Governance for Public Appointment by the Commissioner for Public Appointments.
While two of them are appointed for two years, the other three members have got their terms extended.
Majority of them will have their new term begin in September 2025.
The new board is necessary to support the agency strategy and ensuring overall quality through leadership and advices.
Professor Graham Cooke and Dr Paul Goldsmith have been reappointed as board directors for to two years.
Alongside them, Dr Junaid Bawa and Rajakumari Long have been reappointed for a year – all of them will start their terms in September 2025.
Michael Whitehouse OBE has been reappointed as a non-executive director and Chair of the Audit and Risk Assurance Committee for another year.
Current board members Amanda Calvert and Haider Hussain will end their service with MHRA on August 31, 2025.
The appointed members are expected to dedicate 2-3 days per month to fulfill their duties in the agency.
The annual remuneration for the Non-Executive Director role will be £7,883 while Audit and Risk Assurance Committee Chair will be paid £13,137.
The appointments were based on merit, not politics. Any declared political activity must still be made public.
However, none of the appointees have expressed their political interests yet.
